You are here

Opioid-Free Alternative for Patients with Musculoskeletal Disorders

Combination Pain Reliever Slated for August 2019 Approval

Galt Pharmaceuticals’ Orphengesic Forte has received a priority review goal date for FDA approval by August 14, 2019. The approval will provide physicians and patients with a non-controlled opioid-free alternative for pain management.

Estimates indicate that 47,600 people died from opioid overdoses in 2017 in the U.S. In addition, from July 2016 to September 2017, there was a 30% increase in the use of opioids.

Orphengesic Forte is an oral, non-controlled, combination muscle-relaxant pain reliever. The tablets contain 50 mg orphenadrine citrate, 770 mg aspirin, and 60 mg caffeine. The drug is indicated for the relief of mild to moderate pain in acute musculoskeletal disorders, in combination with rest and physical therapy.

Source: Business Wire, May 30, 2019

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients